POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management

Medicine & Life Sciences

• POEMS Syndrome 100%
• Risk Management 70%
• Plasma Cells 42%
• Polyradiculoneuropathy 33%
• Castleman Disease 30%
• Peripheral Nervous System Diseases 22%
• Plasma Cell Neoplasms 17%
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy 15%
• Lenalidomide 14%
• Paraneoplastic Syndromes 14%
• Thrombocytosis 14%
• Papilledema 13%
• Plasmacytoma 13%
• Thalidomide 13%
• Bortezomib 13%
• Alkylating Agents 12%
• Delayed Diagnosis 11%
• Pleural Effusion 11%
• Stem Cell Transplantation 11%
• Serum Albumin 10%
• Pulmonary Hypertension 10%
• Therapeutics 10%
• Nervous System Diseases 10%
• Vascular Endothelial Growth Factor A 9%
• Adrenal Cortex Hormones 8%
• Disease Progression 8%
• Bone Marrow 7%
• Radiotherapy 7%
• Phenotype 6%
• Bone and Bones 6%
• Skin 5%